TR201901062T4 - Modifiye meningokokal fhbp polipeptidleri. - Google Patents

Modifiye meningokokal fhbp polipeptidleri. Download PDF

Info

Publication number
TR201901062T4
TR201901062T4 TR2019/01062T TR201901062T TR201901062T4 TR 201901062 T4 TR201901062 T4 TR 201901062T4 TR 2019/01062 T TR2019/01062 T TR 2019/01062T TR 201901062 T TR201901062 T TR 201901062T TR 201901062 T4 TR201901062 T4 TR 201901062T4
Authority
TR
Turkey
Prior art keywords
meningococcal fhbp
fhbp polypeptides
modified meningococcal
modified
polypeptides
Prior art date
Application number
TR2019/01062T
Other languages
English (en)
Inventor
Bottomley Matthew
Masignani Vega
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of TR201901062T4 publication Critical patent/TR201901062T4/tr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Buluş sahipleri, meningokokal fHbp varyant 2 ve varyant 3 içinde, bu varyantların özelliklerini geliştirmek maksadıyla modifiye edilebilecek olan artıklar belirleyip tanımlamışlardır.
TR2019/01062T 2014-07-17 2015-07-16 Modifiye meningokokal fhbp polipeptidleri. TR201901062T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14177564 2014-07-17

Publications (1)

Publication Number Publication Date
TR201901062T4 true TR201901062T4 (tr) 2019-02-21

Family

ID=51178812

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/01062T TR201901062T4 (tr) 2014-07-17 2015-07-16 Modifiye meningokokal fhbp polipeptidleri.

Country Status (18)

Country Link
US (2) US11066450B2 (tr)
EP (1) EP3169357B1 (tr)
JP (1) JP2017522320A (tr)
KR (1) KR20170023191A (tr)
CN (1) CN106795208A (tr)
AR (1) AR102324A1 (tr)
AU (1) AU2015289192A1 (tr)
BE (1) BE1022641B1 (tr)
BR (1) BR112017000521A2 (tr)
CA (1) CA2954745A1 (tr)
EA (1) EA201692552A1 (tr)
ES (1) ES2722773T3 (tr)
IL (1) IL249822A0 (tr)
MX (1) MX2017000776A (tr)
SG (1) SG11201610945PA (tr)
TR (1) TR201901062T4 (tr)
WO (1) WO2016008960A1 (tr)
ZA (1) ZA201700170B (tr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012024348B1 (pt) 2010-03-30 2022-11-08 Children's Hospital & Research Center At Oakland Composição imunogênica, seu uso, proteína de ligação ao fator h de ocorrência não natural, e célula bacteriana geneticamente modificada
RS61246B1 (sr) * 2014-02-28 2021-01-29 Glaxosmithkline Biologicals Sa Modifikovani meningokokni fhbp polipeptidi
EA038940B1 (ru) 2014-07-17 2021-11-12 Глаксосмитклайн Байолоджикалс С.А. Менингококковые вакцины
CN106795208A (zh) 2014-07-17 2017-05-31 葛兰素史密丝克莱恩生物有限公司 修饰的脑膜炎球菌fHbp多肽
RU2714248C2 (ru) 2014-07-23 2020-02-13 Чилдрен'З Хоспитал Энд Рисёрч Сентер Эт Окленд Варианты фактор н-связывающего белка и способы их применения
MX2019006105A (es) * 2016-11-25 2019-08-21 Glaxosmithkline Biologicals Sa Conjugados de vmen-antigeno y uso de los mismos.
EP3607967A1 (en) * 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
US11976017B2 (en) 2019-12-19 2024-05-07 Dow Technology Investments Llc Processes for preparing isoprene and mono-olefins comprising at least six carbon atoms
IL305313A (en) 2021-02-19 2023-10-01 Sanofi Pasteur Recombinant meningococcal B vaccine
GB202115151D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Methods
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2024030931A1 (en) 2022-08-03 2024-02-08 Sanofi Pasteur Inc. Adjuvanted immunogenic composition against neisseria meningitidis b

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
ES2507100T3 (es) 2000-01-17 2014-10-14 Novartis Vaccines And Diagnostics S.R.L. Vacuna OMV suplementada contra meningococo
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CA2779816A1 (en) * 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
CN103002910A (zh) 2010-03-10 2013-03-27 葛兰素史密丝克莱恩生物有限公司 疫苗组合物
BR112012024348B1 (pt) 2010-03-30 2022-11-08 Children's Hospital & Research Center At Oakland Composição imunogênica, seu uso, proteína de ligação ao fator h de ocorrência não natural, e célula bacteriana geneticamente modificada
GB201120634D0 (en) 2011-11-30 2012-01-11 Univ Sheffield Adjuvant polypeptide
EP2861247B1 (en) 2012-06-14 2020-12-09 GlaxoSmithKline Biologicals SA Vaccines for serogroup x meningococcus
GB201215005D0 (en) * 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
RS61246B1 (sr) 2014-02-28 2021-01-29 Glaxosmithkline Biologicals Sa Modifikovani meningokokni fhbp polipeptidi
CN106795208A (zh) 2014-07-17 2017-05-31 葛兰素史密丝克莱恩生物有限公司 修饰的脑膜炎球菌fHbp多肽
EA038940B1 (ru) 2014-07-17 2021-11-12 Глаксосмитклайн Байолоджикалс С.А. Менингококковые вакцины

Also Published As

Publication number Publication date
IL249822A0 (en) 2017-03-30
AU2015289192A1 (en) 2017-02-02
ES2722773T3 (es) 2019-08-16
US11939357B2 (en) 2024-03-26
US20220002355A1 (en) 2022-01-06
WO2016008960A1 (en) 2016-01-21
AR102324A1 (es) 2017-02-22
SG11201610945PA (en) 2017-01-27
US11066450B2 (en) 2021-07-20
EP3169357B1 (en) 2018-11-07
KR20170023191A (ko) 2017-03-02
US20170226161A1 (en) 2017-08-10
BE1022641A1 (fr) 2016-06-23
MX2017000776A (es) 2017-05-04
BR112017000521A2 (pt) 2017-11-21
EP3169357A1 (en) 2017-05-24
JP2017522320A (ja) 2017-08-10
BE1022641B1 (fr) 2016-06-23
CN106795208A (zh) 2017-05-31
CA2954745A1 (en) 2016-01-21
EA201692552A1 (ru) 2017-06-30
ZA201700170B (en) 2019-06-26

Similar Documents

Publication Publication Date Title
TR201901062T4 (tr) Modifiye meningokokal fhbp polipeptidleri.
EA201892386A1 (ru) Химерные нейротоксины
EA201691429A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
EA201690280A1 (ru) Композиции и способы, относящиеся к выделенным эндофитам
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
TWD170334S (zh) 垃圾桶之部分
MX2016017108A (es) Composiciones y metodos para el cuidado personal.
AU359433S (en) Cleaner
EA201692254A1 (ru) Иммуномодулирующие прогениторные (имп) клетки
TWD170026S (zh) 容器
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
AU362107S (en) Compressor inlet for turbocharger
MX2017005975A (es) Anticuerpos anti factor de crecimiento derivado de plaquetas b (pdgf-b) y metodos de uso.
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
TWD181502S (zh) 閥之部分
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
AU201710543S (en) Portable Light
TWD174714S (zh) 接合式觸片組之部分
EA202090225A2 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
TWD174083S (zh) 電連接器之部分
AU355238S (en) Dental appliance
TWD180703S (zh) 開關上蓋之部分
AU360397S (en) Extension arm
AU365452S (en) Flat-iron
TWD174084S (zh) 電連接器之部分